Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

DSGN holding history

Design Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

DSGN overviewAll 13F holders of DSGNFull Q2 2026 holdings

Shares (Q2 2026)
34,761
Value
$503.0K
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of DSGN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202634,761$503.0K<0.1%+17,670+103.4%AddedHolders
Q1 202617,091$181.8K<0.1%−8,446−33.1%ReducedHolders
Q4 202525,537$239.5K<0.1%+2,844+12.5%AddedHolders
Q3 202522,693$170.9K<0.1%−4,649−17.0%ReducedHolders
Q2 202527,342$92.1K<0.1%−5,477−16.7%ReducedHolders
Q1 202532,819$126.7K<0.1%−33,768−50.7%ReducedHolders
Q4 202466,587$410.8K<0.1%+51,707+347.5%AddedHolders
Q3 202414,880$80.1K<0.1%+1,520+11.4%AddedHolders
Q2 202413,360$44.8K<0.1%−19,673−59.6%ReducedHolders
Q1 202433,033$133.1K<0.1%−17,408−34.5%ReducedHolders
Q4 202350,441$133.7K<0.1%+32,377+179.2%AddedHolders
Q3 202318,064$42.6K<0.1%−6,098−25.2%ReducedHolders
Q2 202324,162$152.2K<0.1%+23,956+11,629.1%AddedHolders
Q1 2023206$1.19K<0.1%−155,821−99.9%ReducedHolders
Q4 2022156,027$1.60M<0.1%+156,027NewHolders
Q2 20220$00.0%−998−100.0%Sold outHolders
Q1 2022998$16.0K<0.1%+963+2,751.4%AddedHolders
Q4 202135$1.00K<0.1%−1,099−96.9%ReducedHolders
Q3 20211,134$17.0K<0.1%+636+127.7%AddedHolders
Q2 2021498$10.0K<0.1%+198+66.0%AddedHolders
Q1 2021300$9.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.